Catalyst Pharmaceuticals, Inc.
CPRX
$19.96
-$0.66-3.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.16% | 1.43% | 27.46% | 7.57% | 75.27% |
| Total Depreciation and Amortization | 0.00% | 0.02% | 0.07% | 0.17% | 0.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 879.26% | -13.42% | 114.95% | -231.79% | -33.14% |
| Change in Net Operating Assets | 113.42% | -258.56% | -83.20% | 206.13% | 199.99% |
| Cash from Operations | 18.74% | -15.29% | -2.74% | 13.62% | 100.89% |
| Capital Expenditure | -- | -- | 66.02% | -2,490.00% | 94.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 66.02% | -2,490.00% | 94.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -53.83% | -20.00% | 50.43% | 95.86% | -98.57% |
| Repurchase of Common Stock | 65.89% | -38.36% | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.13% | 0.18% | 89.08% | -1,038.67% | 31.13% |
| Cash from Financing | -71.50% | -30.97% | 174.20% | -616.34% | -99.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.33% | -16.11% | 12.88% | 2.08% | -62.22% |